Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Bioage Labs Inc (BIOA)

Bioage Labs Inc (BIOA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
3.82 -0.06 (-1.55%) 03/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 3.76 -0.06 (-1.57%) 16:14 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.80
Day High
3.91
Open 3.85
Previous Close 3.88 3.88
Volume 131,600 131,600
Avg Vol 158,225 158,225
Stochastic %K 3.15% 3.15%
Weighted Alpha N/A N/A
5-Day Change -0.67 (-14.92%) -0.67 (-14.92%)
52-Week Range 3.80 - 26.62 3.80 - 26.62
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 136,947
  • Shares Outstanding, K 35,850
  • Annual Sales, $ 14,940 K
  • Annual Income, $ -98,150 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 245.87% ( +30.27%)
  • Historical Volatility 61.43%
  • IV Percentile 63%
  • IV Rank 30.54%
  • IV High 519.72% on 02/19/25
  • IV Low 125.50% on 03/14/25
  • Put/Call Vol Ratio 18.18
  • Today's Volume 211
  • Volume Avg (30-Day) 123
  • Put/Call OI Ratio 16.62
  • Today's Open Interest 1,832
  • Open Int (30-Day) 1,172

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.52
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.73
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.80 +0.53%
on 03/28/25
Period Open: 4.63
4.68 -18.38%
on 03/03/25
-0.81 (-17.49%)
since 02/28/25
3-Month
3.80 +0.53%
on 03/28/25
Period Open: 5.50
6.02 -36.54%
on 01/02/25
-1.68 (-30.55%)
since 12/27/24

Most Recent Stories

More News
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

BIOA : 3.82 (-1.55%)
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BIOA : 3.82 (-1.55%)
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

BIOA : 3.82 (-1.55%)
BioAge Labs and Novartis Announce Research Collaboration to Accelerate Drug Target Discovery for Aging-Related Diseases

BioAge and Novartis collaborate to identify drug targets for aging-related diseases, with potential funding of $550M.Quiver AI SummaryBioAge Labs, Inc. has announced a multi-year research collaboration...

BIOA : 3.82 (-1.55%)
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

BIOA : 3.82 (-1.55%)
Stocks Settle Lower Ahead of US Inflation News

The S&P 500 Index ($SPX ) (SPY ) Monday closed down -0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.54%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.84%. Stocks on Monday...

IPG : 26.29 (-0.42%)
BIOA : 3.82 (-1.55%)
BIDU : 93.37 (-5.13%)
FTV : 72.63 (-2.63%)
$IUXX : 19,281.40 (-2.61%)
M : 12.81 (-2.81%)
ELV : 432.00 (+0.01%)
UNH : 516.04 (+0.06%)
ZNM25 : 111-165 (+0.28%)
NTES : 100.72 (-1.01%)
PDD : 120.45 (-3.14%)
AMD : 103.22 (-3.22%)
Stocks Weaken Ahead of US Nov CPI Report

The S&P 500 Index ($SPX ) (SPY ) today is down -0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.65%. Stocks today are under pressure,...

IPG : 26.29 (-0.42%)
BIOA : 3.82 (-1.55%)
BIDU : 93.37 (-5.13%)
FTV : 72.63 (-2.63%)
$IUXX : 19,281.40 (-2.61%)
M : 12.81 (-2.81%)
ZNM25 : 111-165 (+0.28%)
NTES : 100.72 (-1.01%)
PDD : 120.45 (-3.14%)
AMD : 103.22 (-3.22%)
$DOWI : 41,583.90 (-1.69%)
SPY : 555.66 (-2.01%)
Stocks Under Pressure from Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.12%. Stocks today are slightly...

APO : 136.96 (-3.57%)
BABA : 132.43 (-2.36%)
NVDA : 109.67 (-1.58%)
IPG : 26.29 (-0.42%)
OMC : 80.24 (-0.48%)
$SPX : 5,580.94 (-1.97%)
BIOA : 3.82 (-1.55%)
SMCI : 34.26 (-1.32%)
BIDU : 93.37 (-5.13%)
FTV : 72.63 (-2.63%)
$IUXX : 19,281.40 (-2.61%)
WDAY : 238.49 (-2.48%)
BioAge Stock Nosedives On Obesity Drug Study Halt: Downgrades Crush Retail Sentiment

BioAge, which had seen strong market interest since its IPO in September amid the weight-loss drug frenzy, is now down over 10% year-to-date.

BIOA : 3.82 (-1.55%)
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BIOA : 3.82 (-1.55%)
BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic on December 19, 2024

BioAge Labs will present its advancements in metabolic disease therapies at the Goldman Sachs Catalyst Clinic on December 19, 2024.Quiver AI SummaryBioAge Labs, a clinical-stage biopharmaceutical company...

BIOA : 3.82 (-1.55%)
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

BIOA : 3.82 (-1.55%)
BioAge Labs to Participate in Upcoming Investor Conferences in December 2024

BioAge Labs will present at two investor conferences in December 2024, focusing on aging-related metabolic disease therapies.Quiver AI SummaryBioAge Labs, a clinical-stage biopharmaceutical company focused...

BIOA : 3.82 (-1.55%)
BioAge Labs to Present at Upcoming Investor Conferences

BIOA : 3.82 (-1.55%)
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

BIOA : 3.82 (-1.55%)
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

BIOA : 3.82 (-1.55%)
BioAge Labs to Present at Jefferies London Healthcare Conference

BIOA : 3.82 (-1.55%)
Prediction: These 2 Stocks Could Soar in 2025

The key word here is "could."

BIOA : 3.82 (-1.55%)
RXRX : 5.81 (-2.68%)
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

The future of the weight loss market might not revolve around GLP-1 drugs.

BIOA : 3.82 (-1.55%)
LLY : 822.51 (+0.10%)
ZLDPF : 76.1000 (-7.08%)
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

BIOA : 3.82 (-1.55%)
LLY : 822.51 (+0.10%)

Business Summary

BioAge Labs Inc. is a clinical-stage biopharmaceutical company. It involved in developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging. BioAge Labs Inc. is based in RICHMOND, Calif.

See More

Key Turning Points

3rd Resistance Point 4.00
2nd Resistance Point 3.95
1st Resistance Point 3.89
Last Price 3.82
1st Support Level 3.78
2nd Support Level 3.73
3rd Support Level 3.67

See More

52-Week High 26.62
Fibonacci 61.8% 17.90
Fibonacci 50% 15.21
Fibonacci 38.2% 12.52
Last Price 3.82
52-Week Low 3.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.